Advertisement

 

 

Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index.

Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index.
Author Information (click to view)

Wasserman S, Meintjes G, Maartens G,


Wasserman S, Meintjes G, Maartens G, (click to view)

Wasserman S, Meintjes G, Maartens G,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Expert review of anti-infective therapy 2016 8 17()

Abstract
INTRODUCTION
Linezolid is an oxazolidinone with potent activity against M tuberculosis, and improves culture conversion and cure rates when added to treatment regimens for drug resistant tuberculosis. However, linezolid has a narrow therapeutic window, and the optimal dosing strategy that minimizes the substantial toxicity associated with linezolid’s prolonged use in tuberculosis treatment has not been determined, limiting the potential impact of this anti-mycobacterial agent.

AREAS COVERED
This paper aims to review and summarize the current knowledge on linezolid for the treatment of drug-resistant tuberculosis. The focus is on the pharmacokinetic-pharmacodynamic determinants of linezolid’s efficacy and toxicity in tuberculosis, and how this relates to defining an optimal dose. Mechanisms of linezolid toxicity and resistance, and the potential role of therapeutic drug monitoring are also covered. Expert commentary: Prospective pharmacokinetic-pharmacodynamic studies are required to define optimal therapeutic targets and to inform improved linezolid dosing strategies for drug-resistant tuberculosis.

Submit a Comment

Your email address will not be published. Required fields are marked *

eighteen − fourteen =

[ HIDE/SHOW ]